Digital Look

Welcome to Digital Look++,
you are not logged in

Ixico (IXI)

Pharma and Biotech

11.25p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
31-Mar-25	Interim	3.21	(0.89)	(1.11)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Sep-20	9.53	0.86	2.02p	48.0	0.4	+120%	n/a	0.0%
30-Sep-21	9.19	1.10	3.17p	25.2	0.4	+57%	n/a	0.0%
30-Sep-22	8.64	0.88	2.14p	15.7	n/a	-32%	n/a	0.0%
30-Sep-23	6.66	(1.36)	(2.44)p	n/a	n/a	n/a	n/a	0.0%
30-Sep-24	5.77	(2.09)	(4.14)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Sep-25	6.30	(2.30)	(2.40)p	n/a	n/a	n/a	n/a	0.0%
30-Sep-26	6.90	(2.20)	(2.40)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	48.02	n/a	15.78	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.